PD-L1 testing and immunotherapy selection – early laboratory experience and its potential role in head and neck cancer management
Abstract
Keywords
Full Text:
PDFReferences
Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010; 15(9):994-1001. doi: 10.1634/theoncologist.2009-0289.
Cadoni G, Giraldi L, Petrelli L, et al. Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy. Fattori prognostici del tumore testa-collo: un’analisi retrospettiva monocentrica di 10 anni. Acta Otorhinolaryngol Ital 2017; 37(6):458-466. doi:10.14639/0392-100X-1246
Denaro N, Merlano MC, Russi EG. Follow-up in head and neck cancer: do more does it mean do better? A systematic review and our proposal based on our experience. Clin Exp Otorhinolaryngol 2016; 9(4):287-297. doi:10.21053/ceo.2015.00976
Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019; 7(1):184. doi: 10.1186/s40425-019-0662-5.
National Institute for Health and Care Excellence. (2018). Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy. [https://www.nice.org.uk/guidance/ta490 available at 06.27.2021]
National Institute for Health and Care Excellence. (2020). Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. [https://www.nice.org.uk/guidance/ta661 available at 06.27.2021]
Kim HS, Lee JY, Lim SH, et al. Association between PD-L1 and HPV status and the prognostic value of PD-L1 in oropharyngeal squamous cell carcinoma. Cancer Res Treat 2016; 48(2):527–536. doi: 10.4143/crt.2015.249
Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol 2018; 86:81–90. doi: 10.1016/j.oraloncology.2018.09.016
Qiao XW, Jiang J, Pang X, et al. The Evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol 2020; 11:1721. doi:10.3389/fimmu.2020.01721
Burtness B, Harrington KJ, Greil R, et al.; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Erratum in: Lancet. 2020; 395(10220):272.
Quenelle NB, Costantini CL. Immunotherapy in head and neck tumors: new options in advanced disease and beyond. J Unexplored Med Data 2018; 3:7. http://dx.doi.org/10.20517/2572-8180.2018.02
DOI: http://dx.doi.org/10.22551/2021.30.0801.10179
Copyright (c) 2021 Andrei Bancu, Richard Cowan, Anshuman Chaturvedi
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975